Stock Analysis on Net
Stock Analysis on Net

Allergan PLC (NYSE:AGN)

$22.49

This company has been moved to the archive! The financial data has not been updated since May 7, 2020.

Balance Sheet: Assets

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.

Paying users area

Try for free

Allergan PLC pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Allergan PLC, consolidated balance sheet: assets

US$ in thousands

Microsoft Excel
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Cash and cash equivalents
Short-term investments
Teva shares
Marketable securities
Accounts receivable, net
Inventories
Current assets held for sale
Prepaid taxes
Prepaid insurance
Contingent income
Sales and marketing
Other
Prepaid expenses and other current assets
Current assets
Property, plant and equipment, net
Right of use asset, operating leases
Deferred executive compensation investments
Equity method investments
Cost method investments
Other long-term investments
Taxes receivable
Contingent income
Other assets
Investments and other assets
Non current assets held for sale
Deferred tax assets
Product rights and other intangibles
Goodwill
Non current assets
Total assets

Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).

Assets: Selected Items

Balance sheet item Description The company
Current assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Allergan PLC current assets decreased from 2017 to 2018 but then increased from 2018 to 2019 not reaching 2017 level.
Property, plant and equipment, net Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. Allergan PLC property, plant and equipment, net increased from 2017 to 2018 and from 2018 to 2019.
Non current assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Allergan PLC non current assets decreased from 2017 to 2018 and from 2018 to 2019.
Total assets Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Allergan PLC total assets decreased from 2017 to 2018 and from 2018 to 2019.

Current Assets: Selected Items

Balance sheet item Description The company
Cash and cash equivalents Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Allergan PLC cash and cash equivalents decreased from 2017 to 2018 but then increased from 2018 to 2019 exceeding 2017 level.
Marketable securities Amount of investment in marketable security, classified as current. Allergan PLC marketable securities decreased from 2017 to 2018 but then increased from 2018 to 2019 not reaching 2017 level.
Accounts receivable, net Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. Allergan PLC accounts receivable, net decreased from 2017 to 2018 but then increased from 2018 to 2019 exceeding 2017 level.
Inventories Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. Allergan PLC inventories decreased from 2017 to 2018 but then increased from 2018 to 2019 exceeding 2017 level.